Fresh analysis indicates that individuals who discontinue new weight-loss injections like semaglutide or tirzepatide may regain lost weight far faster than those who stop traditional lifestyle plans.
Published data in a leading health publication points out that while obese individuals frequently drop a large proportion of their total mass while undergoing treatment, the weight comes back at an estimated rate of 0.8 kg per month upon discontinuation.
"Users purchasing such treatments need to be informed of the potential of quick weight regain when the therapy concludes," stated expert Dr. Susan Jebb.
This pace of regain suggests a reversion to pre-treatment weight in about 18 months.
Weighing Therapies
The research, which reviewed dozens of studies involving thousands of patients, compared the effects of these new drugs with other pills.
The team emphasize that individuals who lose weight through dieting usually have a slower creep back—around 100 grams monthly—after stopping.
The Reason for the Quick Rebound
Experts propose the mechanism of the injections is key to understanding the heightened rebound.
These medications copy a body's own chemical called GLP-1, which moderates appetite.
"Long-term administration of the hormone concentrations several times higher than normal might result in the body to generate a reduced amount of its endogenous hormone, and may also diminish responsiveness to its effects," explained Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this GLP-1 'fix' results in appetite is no longer kept in check, making excessive eating a significant risk."
A Chronic Issue?
The NHS advise the jabs for individuals with obesity-related medical conditions, alongside recommended lifestyle changes.
Many experts contend that, due to the likelihood of relapse, the therapy should be considered long-term.
This view is supported by drug manufacturers, who note that the findings "highlight the chronic nature of obesity," similar to managing conditions like high blood pressure.
User Testimonies
People who have discontinued the jabs report a powerful resurgence of appetite.
"It was like a switch flipping and I was suddenly ravenous," described an individual.
This challenge is exacerbated if users have not developed lasting dietary or behavioural modifications during therapy.
Growing Interest
Recent estimates indicate that millions of people in the UK have used these injections in the past year, with demand continuing to grow.
- Adoption is more common among women compared to males.
- The 40s and 50s age group shows the greatest level of interest.
- Many access the medications through private healthcare rather than the NHS.
Ultimately, clinicians emphasize that while these medications are powerful agents for shedding pounds, they are not a magic cure and lasting health benefits hinges on integrated behavioural management.
